Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Regimens for Visceral Leishmaniasis in Bangladesh
NCT01122771Phase 3Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- May 2010
- Primary completion
- Mar 2014
- Modality
- Lipid-based Nanoparticles, Nucleic Acid-Directed Small Molecules, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of liposomal amphotericin b, miltefosine, paromomycin in visceral leishmaniasis (VL), sponsored by Drugs for Neglected Diseases initiative. Started May 2010; status: completed.
02
Drugs
liposomal amphotericin bmiltefosineparomomycin
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT01122771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01122771.